The Utility of Genome Sequencing as a Diagnostic Tool for Children with Ataxia

ACMG Poster (2026)

PMID

Publication AuthorsXiaonan Zhao, PhD, FACMG, Wilson C.W. Wu, PhD, FACMG, Morgan Driver, PhD, MS, CGC, Elizabeth Fieg, MS, CGC, Robert Rigobello, MS, CGC, Matthew B. Walsh, MMSc, CGC, Jason Chibuk, MS, CGC, Linyan Meng, PhD, FACMG, Fan Xia, PhD, FACMG

Introduction

  • Ataxia is a neurological condition characterized by a lack of muscle coordination resulting in gait instability, impaired fine motor skills, and difficulty with balance and speech.
  • Ataxia can be acquired or inherited, with a heterogeneous group of these disorders including short tandem repeat (STR) disorders, mitochondrial genome disorders, and copy number variants.
  • Compared to exome sequencing (ES) or traditional panel-based testing, genome sequencing (GS) enables a more comprehensive analysis of multiple variant types in a single test, allowing for higher diagnostic yields for genetically and phenotypically heterogenous conditions such as ataxia.
  • However, the diagnostic utility of GS in pediatric cohorts with ataxia is still being assessed and is not
    well-described in the literature.
  • Here, we describe our clinical laboratory experience with GS and testing individuals with ataxia.
image_print